Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Literature DB >> 31802110

Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Ryan K Shields^1,2, Yohei Doi^1,2,3.

Abstract

Entities: Chemical

Keywords: beta-lactamase inhibitor; carbapenemase; monobactam; pharmacokinetics

Year: 2020 PMID： 31802110 PMCID： PMC7428391 DOI： 10.1093/cid/ciz1159

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

× No keyword cloud information.

25 in total

1. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors: Jared L Crandon; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2013-05-06 Impact factor: 5.191

Review 2. Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates.

Authors: Pranita D Tamma; Patricia J Simner
Journal: J Clin Microbiol Date: 2018-10-25 Impact factor: 5.948

Review 3. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.

Authors: Ryan L Crass; Manjunath P Pai
Journal: Pharmacotherapy Date: 2019-01-20 Impact factor: 4.705

4. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.

Authors: Evelyn Shaw; Alexander Rombauts; Fe Tubau; Ariadna Padullés; Jordi Càmara; Toni Lozano; Sara Cobo-Sacristán; Núria Sabe; Imma Grau; Raül Rigo-Bonnin; M Angeles Dominguez; Jordi Carratalà
Journal: J Antimicrob Chemother Date: 2018-04-01 Impact factor: 5.790

5. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors: Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191

6. Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.

Authors: M Biagi; T Wu; M Lee; S Patel; D Butler; E Wenzler
Journal: Antimicrob Agents Chemother Date: 2019-09-30 Impact factor: 5.191

7. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors: Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191

8. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors: Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191

Review 9. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors: Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal: Antimicrob Agents Chemother Date: 2013-12-30 Impact factor: 5.191

10. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Authors: Richard G Wunderink; Evangelos J Giamarellos-Bourboulis; Galia Rahav; Amy J Mathers; Matteo Bassetti; Jose Vazquez; Oliver A Cornely; Joseph Solomkin; Tanaya Bhowmick; Jihad Bishara; George L Daikos; Tim Felton; Maria Jose Lopez Furst; Eun Jeong Kwak; Francesco Menichetti; Ilana Oren; Elizabeth L Alexander; David Griffith; Olga Lomovskaya; Jeffery Loutit; Shu Zhang; Michael N Dudley; Keith S Kaye
Journal: Infect Dis Ther Date: 2018-10-01

12 in total

1. Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?

Authors: Ryan K Shields
Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191

2. Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Authors: Abiu Sempere; Belén Viñado; Ibai Los-Arcos; David Campany; Nieves Larrosa; Nuria Fernández-Hidalgo; Dolors Rodríguez-Pardo; Juan José González-López; Xavier Nuvials; Benito Almirante; Laura Escolà-Vergé
Journal: Antimicrob Agents Chemother Date: 2022-09-14 Impact factor: 5.938

3. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.

Authors: Mustafa Sadek; Mario Juhas; Laurent Poirel; Patrice Nordmann
Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191

Review 4. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Authors: Juan C Vázquez-Ucha; Jorge Arca-Suárez; Germán Bou; Alejandro Beceiro
Journal: Int J Mol Sci Date: 2020-12-06 Impact factor: 5.923

Review 5. A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors: Toni A Campanella; Jason C Gallagher
Journal: Infect Drug Resist Date: 2020-11-25 Impact factor: 4.003

6. New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria, Switzerland, 2019-2020.

Authors: Jacqueline Findlay; Laurent Poirel; Julie Kessler; Andreas Kronenberg; Patrice Nordmann
Journal: Emerg Infect Dis Date: 2021-10 Impact factor: 6.883

Review 7. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.

Authors: Mark S Butler; Valeria Gigante; Hatim Sati; Sarah Paulin; Laila Al-Sulaiman; John H Rex; Prabhavathi Fernandes; Cesar A Arias; Mical Paul; Guy E Thwaites; Lloyd Czaplewski; Richard A Alm; Christian Lienhardt; Melvin Spigelman; Lynn L Silver; Norio Ohmagari; Roman Kozlov; Stephan Harbarth; Peter Beyer
Journal: Antimicrob Agents Chemother Date: 2022-01-10 Impact factor: 5.191